Oligodendroglioma Drug Profiles and Clinical Trials- Global Trends and Analysis Review, H1 2018

  • ID: 4460444
  • Report
  • Region: Global
  • 112 Pages
  • VPA Research
1 of 4
This Research Analyzes the Evolution of Glioma Clinical Trial Trends Across Countries and Regions

Glioma clinical trials report provides comprehensive analysis and trends in global Glioma disease clinical trials. The research work analyzes the evolution of Glioma clinical trial trends across countries and regions.

The report focuses on drugs and therapies being evaluated for Glioma treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner offering quick access to Glioma clinical trials.

Major drugs under development in Glioma are provided in the report along with their details of mechanism of action, route of administration, target, therapy, molecule and class.

Scope of the Report:

  • Number of Glioma clinical trials across regions- Asia and Oceania, Europe, Middle East Africa and Americas
  • Trial information by Phase and Subjects recruited
  • Trial information by status, type, sponsor type
  • Drugs used for treatment of Glioma
  • Both observational and interventional trials analyzed
  • Success rates of trials are analyzed
  • Trends in enrollment over the past ten years identified
  • Leading sponsors of Glioma clinical trials worldwide are listed

Reasons to Buy:

  •  Track competition and design competitive advantages
  •  Identify right partners to associate with for further research
  •  Evaluate potential opportunities available in further clinical trials of the disease
  •  Formulate business development strategies through success rates of clinical trials
  •  Identify quick markets for recruiting subjects based on trials count by each market

Glioma - The condition occurs when the glial cells in the brain are affected and account for around one-third of all brain tumors. On the basis of location, these are classified as supratentorial (above tentorium) and infratentorial (below tenotrium).

On the basis of pace of development, these are categorized as Low grade (grades 1 and 2) and high grade (3 and 4). Treatment options vary with the grade of the disease, but most often it includes a combination of medicine, surgery, radiation and chemo therapies.

Malignant Glioma - Malignant Glioma is the most regular subtypes of glioma condition occurring in patients aged between 60 and 80. The condition is classified as grade 3 and grade 4, which comprises anaplastic high-grade gliomas and glioblastomas respectively.

High Grade Glioma - Malignant or high-grade glioma tumors are categorized as Grade 3 and Grade 4. Of this Grade 3 tumor types include -

Anaplastic astrocytoma - The rare disease type comprises an estimated one-third of all astrocytoma types. Often observed in older persons, the condition can occur in any aged person. Astrocytoma emerges from star shaped cells in the brain, called astrocytes.

Anaplastic oligodendroglioma - It is a rare type of malignant tumor occurring mainly between 45 and 50 years of age. They possess abnormal genetic material and unique molecular, clinical, and histological characteristics and are important to diagnose.

Anaplastic oligoastrocytoma - Oligoastrocytoma occurs when either oligodendrocytes and astrocytes or both grow rapidly, causing formation of tumors in the brain. The term ‘Anaplastic’ refers to condition when tumor can spread into nearby tissues. They occur in Cerebrum area.

Anaplastic ependymoma - The fast growing subtype occurs primarily in posterior fossa part. The tumor cells show rapid growth pace and are associated with a less favorable prognosis and have higher possibility to infiltrate around the brain or disseminate into cerebrospinal fluid resulting in drop metastases.

Glioblastoma - The grade 4 type condition is further classified as primary and secondary types. The primary subtype occurs without earlier diagnosis of low grade tumors while the secondary type arouses from development of grade 2 or 3 subtypes. Tumor occurs as a result of accumulation of different mutations.

Pontine Gliomas - Diffuse intrinsic pontine glioma (DIPG) is an aggressive type of malignant glioma, arising from glioma tissue. As these are observed in the bottom area of the brain, they are tough to be treated. It is observed mostly in children.

Low Grade Glioma (LGGs) or often referred to as Grade-1 and 2 tumors, arouse from brain cells including astrocytes and oligodendrocytes. Causing mild and large seizures, the Glioma type is treated through a combination of surgery, chemotherapy, and radiation on the basis of disease condition. The condition is primarily observed in young and healthy individuals. Compared to high grade Glioma, these patients survive for long periods and lead quality life as this is a slow growth disease.

On the basis of appearance under microscope and genetic modifications, Low grade gliomas are classified as-
Pilocytic astrocytomas - Observed in adults aging less than 25 and progresses very slowly compared to other types

Diffuse astrocytomas - Most observed subtype of low-grade glioma. Late 30’s individuals are the most affected age. Type of modification in IDH isocitrate-dehydrogenase gene determines the sub-types of Diffuse astrocytomas.

Oligodendrogliomas - Slow growing tumors, having mutation in the IDH gene in terms of missing 1p and 19q chromosomes.

Gangliogliomas - Posesses both gliomas and tumor related characteristics.

READ MORE
Note: Product cover images may vary from those shown
2 of 4

1 Table of Contents
1.1 List of Figures
1.2 List of Tables

2 Executive Summary
2.1 Report Guide
2.2 Key Findings
2.2.1 Overview of Global Clinical Trials Initiated in 2017
2.2.2 Average Enrolment by Country, 2010 - 2017
2.2.3 Prominent Companies in Global Oligodendroglioma Trials, 2010 - 2017

3 Oligodendroglioma Drugs in Ongoing and Completed Trials
3.1 Prominent Drugs in Development and Approved Stages for Oligodendroglioma
3.2 Oligodendroglioma Product Snapshots
3.2.1 Oligodendroglioma Drug Profiles

4 Global Oligodendroglioma Clinical Trial Research Trends
4.1 Clinical Trials by Top 10 Countries, 2010 - 2017
4.1.1 Clinical Trials by Country
4.1.2 Number of Ongoing/Planned Trial Locations in Each Country
4.2 Subjects Recruited by Top 10 Countries, 2010 - 2017
4.2.1 Total Enrolment by Country
4.3 Clinical Trials by Region, 2010 - 2017
4.4 Subjects Recruited by Region, 2010 - 2017
4.5 Clinical Trials by Year, 2010 - 2017
4.6 Subjects Recruited by Year, 2010 - 2017
4.7 Clinical Trials by Development Phase, 2010 - 2017
4.7.1 Clinical Trials by Phase
4.8 Subjects Recruited by Development Phase, 2010 - 2017
4.9 Clinical Trials by Status, 2010 - 2017
4.10 Subjects Recruited by Trial Status, 2010 - 2017
4.11 Clinical Trials by Sponsor Type, 2010 - 2017
4.12 Subjects Recruited by Sponsor Type, 2010 - 2017
4.13 Clinical Trials by Economy Type, 2010 - 2017
4.14 Clinical Trials and Subjects Recruited by Study Type, 2010 - 2017

5 Europe Oligodendroglioma Clinical Trial Research Trends
5.1 Clinical Trials by Top Countries in Europe, 2010 - 2017
5.1.1 Europe, Clinical Trials by Country
5.2 Subjects Recruited by Top Countries in Europe, 2010 - 2017
5.2.1 Europe, Total Enrolment by Country
5.3 Europe, Clinical Trials by Year, 2010 - 2017
5.4 Europe, Clinical Trials by Development Phase, 2010 - 2017
5.5 Europe, Clinical Trials by Trial Status, 2010 - 2017
5.6 Europe, Clinical Trials by Sponsor Type, 2010 - 2017

6 North America Oligodendroglioma Clinical Trial Research Trends
6.1 Clinical Trials by Top Countries in North America, 2010 - 2017
6.1.1 North America, Clinical Trials by Country
6.2 Subjects Recruited by Top Countries in North America, 2010 - 2017
6.2.1 North America, Total Enrolment by Country
6.3 North America, Clinical Trials by Year, 2010 - 2017
6.4 North America, Clinical Trials by Development Phase, 2010 - 2017
6.5 North America, Clinical Trials by Trial Status, 2010 - 2017
6.6 North America, Clinical Trials by Sponsor Type, 2010 - 2017

7 Western Pacific Oligodendroglioma Clinical Trial Research Trends
7.1 Clinical Trials by Top Countries in Western Pacific, 2010 - 2017
7.1.1 Western Pacific, Clinical Trials by Country
7.2 Subjects Recruited by Top Countries in Western Pacific, 2010 - 2017
7.2.1 Western Pacific, Total Enrolment by Country
7.3 Western Pacific, Clinical Trials by Year, 2010 - 2017
7.4 Western Pacific, Clinical Trials by Development Phase, 2010 - 2017
7.5 Western Pacific, Clinical Trials by Trial Status, 2010 - 2017
7.6 Western Pacific, Clinical Trials by Sponsor Type, 2010 - 2017

8 Recent Clinical Trials - Snapshots
8.1 Oligodendroglioma Trial Snapshots - 2018
8.2 Oligodendroglioma Trial Snapshots - 2017
8.3 Oligodendroglioma Trial Snapshots - 2016
8.4 Oligodendroglioma Trial Snapshots - 2015
8.5 Oligodendroglioma Trial Snapshots - 2014
8.6 Oligodendroglioma Trial Snapshots - 2013
8.7 Oligodendroglioma Trial Snapshots - 2012
8.8 Oligodendroglioma Trial Snapshots - 2011
8.9 Oligodendroglioma Trial Snapshots - 2010

9 Appendix
9.2 Sources and Research Methodology

1.1 List of Figures
Figure 1: Oligodendroglioma - Average Enrolment by Country, 2010 - 2017
Figure 2: Oligodendroglioma - Country wise Clinical Trials, 2010 - 2017
Figure 3: Oligodendroglioma - Country wise Recruiting Sites, 2010 - 2017
Figure 4: Oligodendroglioma - Country wise Subjects Recruited, 2010 - 2017
Figure 5: Global Oligodendroglioma Clinical Trials Participation Share by Region, 2010 - 2017  
Figure 6: Global Oligodendroglioma Subjects Recruited by Region, 2010 - 2017
Figure 7: Global Oligodendroglioma Clinical Trials by Year, 2010 - 2017
Figure 8: Global Oligodendroglioma Subjects Recruited by Year, 2010 - 2017
Figure 9: Global Oligodendroglioma Trials by Phase, 2010 - 2017
Figure 10: Global Oligodendroglioma - Subjects Recruited by Phase, 2010 - 2017
Figure 11: Global Oligodendroglioma - Clinical Trials by Recruitment Status, 2010 - 2017
Figure 12: Global Oligodendroglioma - Subjects Recruited by Trial Status, 2010 - 2017
Figure 13: Global Oligodendroglioma - Clinical Trials by Sponsor Type, 2010 - 2017
Figure 14: Global Oligodendroglioma - Subjects Recruited by Trial Status, 2010 - 2017
Figure 15: Global Oligodendroglioma - Clinical Trials by Type of Economy, 2010 - 2017
Figure 16: Europe Oligodendroglioma - Country wise Clinical Trials, 2010 - 2017
Figure 17: Europe Oligodendroglioma - Country wise Subjects Recruited, 2010 - 2017
Figure 18: Europe Oligodendroglioma - Year wise Clinical Trials, 2010 - 2017
Figure 19: Europe Oligodendroglioma Trials by Phase, 2010 - 2017
Figure 20: Europe Oligodendroglioma - Clinical Trials by Recruitment Status, 2010 - 2017
Figure 21: Europe Oligodendroglioma - Clinical Trials by Sponsor Type, 2010 - 2017
Figure 22: North America Oligodendroglioma - Country wise Clinical Trials, 2010 - 2017
Figure 23: North America Oligodendroglioma - Country wise Subjects Recruited, 2010 - 2017
Figure 24: North America Oligodendroglioma - Year wise Clinical Trials, 2010 - 2017
Figure 25: North America Oligodendroglioma Trials by Phase, 2010 - 2017
Figure 26: North America Oligodendroglioma - Clinical Trials by Recruitment Status, 2010 - 2017 
Figure 27: North America Oligodendroglioma - Clinical Trials by Sponsor Type, 2010 - 2017
Figure 28: Western Pacific Oligodendroglioma - Country wise Clinical Trials, 2010 - 2017
Figure 29: Western Pacific Oligodendroglioma - Country wise Subjects Recruited, 2010 - 2017
Figure 30: Western Pacific Oligodendroglioma - Year wise Clinical Trials, 2010 - 2017
Figure 31: Western Pacific Oligodendroglioma Trials by Phase, 2010 - 2017
Figure 32: Western Pacific Oligodendroglioma - Clinical Trials by Recruitment Status, 2010 - 2017 
Figure 33: Western Pacific Oligodendroglioma - Clinical Trials by Sponsor Type, 2010 - 2017

1.2 List of Tables
Table 1: Oligodendroglioma Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target
Table 2: Oligodendroglioma Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target
Table 3: Oligodendroglioma Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target
Table 4: Oligodendroglioma - Region wise Clinical Trials, 2010 - 2017
Table 5: Oligodendroglioma - Region wise Subjects Recruited, 2010 - 2017
Table 6: Global Oligodendroglioma - Clinical Trials and Subjects by Trial Type, 2010 - 2017
Table 7: Oligodendroglioma Trial Snapshots - 2018
Table 8: Oligodendroglioma Trial Snapshots - 2017
Table 9: Oligodendroglioma Trial Snapshots - 2017
Table 10: Oligodendroglioma Trial Snapshots - 2017
Table 11: Oligodendroglioma Trial Snapshots - 2017
Table 12: Oligodendroglioma Trial Snapshots - 2017
Table 13: Oligodendroglioma Trial Snapshots - 2017
Table 14: Oligodendroglioma Trial Snapshots - 2017
Table 15: Oligodendroglioma Trial Snapshots - 2017
Table 16: Oligodendroglioma Trial Snapshots - 2016
Table 17: Oligodendroglioma Trial Snapshots - 2016
Table 18: Oligodendroglioma Trial Snapshots - 2016
Table 19: Oligodendroglioma Trial Snapshots - 2016
Table 20: Oligodendroglioma Trial Snapshots - 2016
Table 21: Oligodendroglioma Trial Snapshots - 2016
Table 22: Oligodendroglioma Trial Snapshots - 2015
Table 23: Oligodendroglioma Trial Snapshots - 2015
Table 24: Oligodendroglioma Trial Snapshots - 2015
Table 25: Oligodendroglioma Trial Snapshots - 2014
Table 26: Oligodendroglioma Trial Snapshots - 2014
Table 27: Oligodendroglioma Trial Snapshots - 2014
Table 28: Oligodendroglioma Trial Snapshots - 2014
Table 29: Oligodendroglioma Trial Snapshots - 2014
Table 30: Oligodendroglioma Trial Snapshots - 2014
Table 31: Oligodendroglioma Trial Snapshots - 2013
Table 32: Oligodendroglioma Trial Snapshots - 2013
Table 33: Oligodendroglioma Trial Snapshots - 2013
Table 34: Oligodendroglioma Trial Snapshots - 2013
Table 35: Oligodendroglioma Trial Snapshots - 2013
Table 36: Oligodendroglioma Trial Snapshots - 2012
Table 37: Oligodendroglioma Trial Snapshots - 2012
Table 38: Oligodendroglioma Trial Snapshots - 2012
Table 39: Oligodendroglioma Trial Snapshots - 2012
Table 40: Oligodendroglioma Trial Snapshots - 2012
Table 41: Oligodendroglioma Trial Snapshots - 2012
Table 42: Oligodendroglioma Trial Snapshots - 2012
Table 43: Oligodendroglioma Trial Snapshots - 2012
Table 44: Oligodendroglioma Trial Snapshots - 2012
Table 45: Oligodendroglioma Trial Snapshots - 2012
Table 46: Oligodendroglioma Trial Snapshots - 2012
Table 47: Oligodendroglioma Trial Snapshots - 2012
Table 48: Oligodendroglioma Trial Snapshots - 2012
Table 49: Oligodendroglioma Trial Snapshots - 2011
Table 50: Oligodendroglioma Trial Snapshots - 2011
Table 51: Oligodendroglioma Trial Snapshots - 2011
Table 52: Oligodendroglioma Trial Snapshots - 2011
Table 53: Oligodendroglioma Trial Snapshots - 2011
Table 54: Oligodendroglioma Trial Snapshots - 2010
Table 55: Oligodendroglioma Trial Snapshots - 2010
Table 56: Oligodendroglioma Trial Snapshots - 2010
Table 57: Oligodendroglioma Trial Snapshots - 2010
Table 58: Oligodendroglioma Trial Snapshots - 2010
Table 59: Oligodendroglioma Trial Snapshots - 2010
Table 60: Oligodendroglioma Trial Snapshots - 2010
Table 61: Oligodendroglioma Trial Snapshots - 2010
Table 62: Oligodendroglioma Trial Snapshots - 2010
Table 63: Oligodendroglioma Trial Snapshots - 2010
Table 64: Oligodendroglioma Trial Snapshots - 2010

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll